Skip to content
Screener

Taysha Gene Therapies, Inc. TSHA Q4 2025 Annual earnings

Reported March 19, 2026 · Before market open

Revenue$5.5MBeat by $3.2M
EPS-$0.08Beat by $0.03
Revenue estimate$2.2M
EPS estimate-$0.11

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$755.6K
EPS estimate-$0.14

Financials

Q4 2025

Income statement

See full
Revenue$5.5M+171%
Operating income-$28.3M-42.0%
Net income-$27.9M-48.3%
EPS (diluted)-$0.08-14.3%

Balance sheet

See full
Cash & equivalents$319.8M+130%
Total debt$70.1M+10.4%
Total equity$246.9M+245%
Total assets$343.3M+114%

Cash flow

See full
Operating cash flow-$26.7M-46.0%
CapEx$250.0K—
Free cash flow-$27.0M-47.3%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.51B+325%
Enterprise value$1.26B+350%
P/S154.2×+112×

Profitability

See full
Operating margin-1,130.6%+35.2pp
Net margin-1,115.3%+47.4pp
FCF margin-960.1%-18.4pp

Returns & leverage

See full
Return on equity-68.5%-20.9pp
Debt / equity0.3×-0.6×
Current ratio12.2×+6.8×

FAQ

When did Taysha Gene Therapies, Inc. report Q4 2025 earnings?
Taysha Gene Therapies, Inc. (TSHA) reported Q4 2025 earnings on March 19, 2026 before market open.
What were Taysha Gene Therapies, Inc.'s Q4 2025 revenue and EPS?
Taysha Gene Therapies, Inc. reported revenue of $5.5M and eps of $-0.08 for Q4 2025.
Did Taysha Gene Therapies, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $2.2M by $3.2M. EPS beat the consensus estimate of $-0.11 by $0.03.
How did Taysha Gene Therapies, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 171.2% from $2.0M a year earlier and eps declined 14.3% from $-0.07.
Where can I find Taysha Gene Therapies, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-115177) and the 10-K periodic report (0001193125-26-115202) directly on SEC EDGAR. The filing index links above go to sec.gov.